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toxicities as well as costs, with minimal expected benefits to patients' survival or quality of life. 5 Thus, appropriate use of hospice and palliative care services has the potential to improve patient outcomes, prevent unwanted suffering, and reduce health care costs at EOL.
Hospice is a medical service focused on EOL care that benefits both patients and families. [6] [7] [8] Family members of patients who receive hospice services report greater satisfaction with care, higher quality of death for the patient, and improved psychological outcomes compared with families of patients who do not receive hospice care. 6 Unfortunately, patients often are admitted to hospice too late to derive many of these benefits. 9 Estimates suggest that nearly 15% of patients with cancer enroll in hospice in the last 3 days of life. 9, 10 Overall, the median LOS for patients with cancer enrolled in hospice is only about 2 to 3 weeks. [10] [11] [12] [13] Thus, the American Society of Clinical Oncology guidelines recommend hospice enrollment prior to death as a metric for high quality cancer care, and quality improvement initiatives have begun tracking 3-and 7-day hospice LOS. 14 Despite these recommendations and the mounting evidence of the benefits of hospice for patients with cancer, little is known about hospice use among MG patients.
In this retrospective study, we sought to evaluate the rates and correlates of hospice use among patients with MG utilizing the Surveillance, Epidemiology, and End Results (SEER)-Medicare database. In addition to describing the proportion of MG patients enrolled in hospice and their LOS in hospice, we also aimed to identify predictive factors for overall hospice enrollment and hospice LOS. By describing the use of hospice services among patients with MG and identifying factors associated with hospice enrollment, findings from this work have the potential to inform future investigations seeking to enhance EOL care for patients with MG.
Methods
Data Source
The SEER database includes information about incident cancer cases from 17 affiliated cancer registries, covering approximately 26% of the US population. These data include information for patients between January 1, 1973 and December 31, 2012. The Medicare-linked database contains information from the Centers for Medicare and Medicaid Services for patients with cancer 15 and includes information about the use of hospice services by patients enrolled in fee-for-service Medicare. The study was determined to be exempt by the Partners HealthCare institutional review board.
Study Sample
We used the SEER-Medicare database to retrospectively identify patients 18 years of age or older who were diagnosed with MG (histology of anaplastic astrocytoma, glioblastoma, or anaplastic oligodendroglioma) and subsequently passed away between January 1, 2002 and December 31, 2012. We excluded the 13.7% of patients who did not have fee-for-service Medicare insurance, as well as those patients who were diagnosed with MG after entering hospice, or who were diagnosed with MG at autopsy.
Patient Demographic and Clinical Characteristics
We obtained data about patients' sociodemographic and clinical characteristics from the linked SEER-Medicare dataset. We collected baseline patient demographic information, including age at diagnosis, sex, race/ethnicity, marital status, and urban versus rural residence. To estimate household income and level of education, we used patient zip codes to identify county of residence, and we linked this information to county-level median income and education data. As malignant gliomas do not have a recognized staging system, we did not collect additional extent of disease information. We also collected treatment characteristics, including extent of surgical resection (dichotomized into biopsy or subtotal resection versus gross total resection) and whether patients received radiation therapy.
Outcome Measures
To characterize differences in hospice use, we evaluated the following: enrollment in hospice prior to death (yes vs no), LOS in hospice (continuous variable, measured in days), LOS in hospice >3 days (yes vs no), and LOS in hospice >7 days (yes vs no). We defined enrollment in hospice prior to death as any patient who received inpatient, outpatient, or home-based hospice services, but excluding palliative care consultation as a sole indicator of hospice use, at any time between their date of MG diagnosis and date of death. We defined death while enrolled in hospice as any patient whose month and year of death matched the
Importance of the study
We present an analysis of end-of-life care for patients with malignant glioma as determined by analysis of SEER-Medicare data. Of the >12 000 patients included in this study, we found that over 60% enrolled in hospice before death, and the vast majority of those met lengthof-stay landmarks of 3 and 7 days, which are associated with higher quality end-of-life care. We explore predictors of hospice utilization and length of stay, including demographic and socioeconomic factors. This work not only highlights an understudied component of malignant glioma care, but also demonstrates potential disparities in care that warrant additional study. month and year of hospice termination. We calculated LOS in hospice by measuring days from hospice enrollment until death. We used hospice enrollment 3 days or less and 7 days or less prior to death as potential measures of suboptimal EOL care. 14 
Statistical Analysis
We performed all analyses using SAS version 9.4. We separated patients into 2 groups based on whether they enrolled in hospice prior to death. We used descriptive statistics to evaluate baseline features of each of these cohorts and univariate logistic regression analyses to compare socioeconomic, demographic, and treatment characteristics between hospice recipients and nonrecipients. We performed multivariable logistic regression analyses to examine predictors of hospice enrollment with regard to >3-or >7-day duration of hospice care prior to death. We included the following variables: age at diagnosis, sex (male or female), race (white, black, Hispanic, Asian, all others), marital status (married, unmarried, or unknown), extent of surgery (biopsy/subtotal resection, gross total resection, or unknown), treatment with radiation (received, not received, or unknown), median household income by zip code, residence in a rural zip code (yes or no), and level of education (percentage of adults age ≥25 y with a high school education, based on zip code and assessed at the county level). We chose these variables based on previously described predictors of hospice utilization in patients with cancer and prognostic factors for patients with MG. [16] [17] [18] [19] [20] We used a Kaplan-Meier analysis to summarize duration of hospice enrollment for all patients. Table 1 displays patient characteristics. The total sample size of 12 437 included 7849 patients (63.1%) enrolled in hospice prior to death and 4588 (36.9%) not enrolled in hospice prior to death. In both cohorts, the majority of patients were male, white, and married and lived in nonrural zip codes. Hospice recipients were older than nonhospice recipients, with mean age at diagnosis of 72.01 years (SD 9.84) in the hospice cohort compared with 67.90 years (SD 12.03) in the nonhospice group (P < 0.0001). Hospice recipients were also more likely than nonhospice recipients to be female, white, and unmarried. Seventy-seven percent of hospice claims filed were for inpatient services, while the remainder were either for home or non-acute inpatient care (eg, nursing facility).
Results
To evaluate patterns of hospice use over the decade studied, we explored the proportion of patients in our cohort 
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who received hospice services prior to death within each of the disease groups (Fig. 1A) . The proportion of patients receiving hospice was relatively stable per year for glioblastoma and anaplastic astrocytoma diagnoses, with the exception of the last 2 years of the studied period, which likely reflects that patients had not yet approached end of life by our study cutoff date of December 31, 2012. Notably, hospice use for anaplastic oligodendroglioma was generally lower than the other 2 included pathologies but was overall stable as well, aside from some moderate fluctuation and a similar decrease in usage near the study end. Overall, 92.7% of patients who enrolled in hospice died on hospice.
To determine factors associated with hospice utilization, we performed multivariable logistic regression modeling ( Fig. 1B) Hospice LOS for the entire cohort (n = 7849) was estimated using Kaplan-Meier analysis of survival from the time of hospice enrollment, with results shown in Fig. 2 . Median LOS in hospice was 21 days, with interquartile range of 8-45 days.
We also used multivariable logistic regression to evaluate predictors of length of stay in hospice of greater than 3 and 7 days (Table 2 ). In the entire cohort of 7849 patients enrolled in hospice, 6996 patients (89.1%) were enrolled more than 3 days before death, and 6047 patients (77.0%) were enrolled in hospice more than 7 days before death. There were higher odds of a short stay in hospice, defined as enrollment in hospice within 3 days of death or within 7 days of death, in patients who were younger, male, and/or residing in a rural area. Although race, education, and household income were predictors of hospice enrollment, they were not associated with LOS in hospice greater than 3 and 7 days. There was no significant change in the proportion of patients with at least 3-or 7-day enrollment over the years studied.
Discussion
In this large, retrospective study utilizing SEER-Medicare data, we found that over 60% of patients with MG enrolled in hospice prior to death, a proportion that was relatively stable over time. Importantly, we also identified certain patient characteristics, such as age and sex, that are associated with whether patients receive hospice services prior to death. In addition, for those patients who received hospice services, we found that most were enrolled in hospice greater than 7 days prior to death, yet nearly 25% only received hospice care for under a week. Notably, we identified similar characteristics, such as age and sex, that were associated with whether patients received hospice services greater than 3 or 7 days prior to death. Thus, our findings provide valuable new insights about the rates and correlates of hospice use among patients with MG.
Despite recommendations from professional organizations to track hospice use among patients with cancer, 14 little research exists with regard to current EOL practices for patients with MG. Previous studies have demonstrated rates and correlates of hospice use among a broad range of non-CNS cancer types. [21] [22] [23] [24] [25] [26] [27] Although one prior study investigated late referrals to home hospice in patients with primary malignant brain tumors, 16 no studies to date have described overall patterns and predictors of hospice referral in this population. As MGs are extremely aggressive cancers with a dismal prognosis, EOL care is of utmost importance for patients. Notably, we found that over 60% of patients with MG received hospice prior to death, which was relatively stable over the decade studied. Although treatments evolved over this interval, this highlights the ingrained practice pattern of hospice referral before end of life for a majority of MG patients regardless of therapies received. This hospice enrollment rate is similar to those seen in other cancer populations. 8, 28 Similarly, this matches the self-reported rate of hospice use among neuro-oncology providers surveyed regarding palliative care practices; the majority of neuro-oncology clinicians in the US and Canada (63%) reported referring more than 50% of their patients to hospice for EOL care; 44% of respondents reported referring >75% of their patients with MG to hospice. 29 Importantly, we found that median LOS in hospice in our study was 3 weeks. However, nearly a quarter of MG hospice recipients enrolled in hospice in the last week of life, and 11% spent 3 or fewer days in hospice prior to death. These are lower than the percentage of short hospice stays previously noted in the oncology literature, where reports suggest that 14.3% of patients with cancer enroll in hospice within 3 days of death, with significant variability by cancer type in the percentage of hospice enrollees with short stays. 9, 12, 13 Concordant with this finding, previous studies also have demonstrated a pattern of earlier hospice referral for patients with CNS tumors and longer stays in hospice compared with other solid tumors. 12, 13 The reasons for longer hospice LOS for patients with MG are largely unknown, but may be related to the aggressive nature of these tumors, which may prompt earlier EOL care discussions between patients and clinicians. Alternatively, prognosis may be more reliably predicted for patients with MG than other cancer types, thereby resulting in earlier EOL discussions and hospice referrals. Moreover, perhaps cultural/training differences exist between neuro-oncologists and other solid tumor oncologists, and this warrants further investigation. Thus, although we found high rates of hospice enrollment among patients with MG, additional research is needed to better understand the reasons for 
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We found lower odds of hospice enrollment for younger, male, less educated, nonwhite, and rural-dwelling patients. Prior studies of disparities in hospice utilization have demonstrated that substantial barriers to hospice access exist for racial and ethnic minorities. Although the cause of this disparity is not entirely understood, studies suggest that cultural differences and socioeconomic factors may play a role. [30] [31] [32] [33] Rural residence, male sex, and younger age have an established association with decreased hospice utilization in other cancer populations. 21, 34, 35 We also found higher risk of shorter hospice LOS in male, younger, and rurally based patients. Previous studies have shown that hospice LOS for minorities is generally equal to or longer than that for whites 18, 31 ; similarly, we found no association between race and duration of hospice use.
This study has several limitations. First, our analysis of factors associated with hospice services is limited to factors available in the SEER-Medicare-linked database. Thus, we lack information about patient preferences, functional impairments, physician characteristics, and other factors that may potentially influence hospice use. Second, our study population is restricted to patients with fee-for-service Medicare living within areas included in the SEER program of population-based cancer registries. This may limit the generalizability of our findings to patients outside of this population. In addition, the SEER-Medicare database only allows for assessment of socioeconomic variables such as level of education and income based on zip code of residence and assessed at the county level. In contrast to the bevy of literature demonstrating reduced access to and/or utilization of palliative care services and hospice for low-income patients, 17, [36] [37] [38] we found that the odds of hospice enrollment were lower with increasing household income. While it is possible that this is a true association due to unclear factors in this patient population, we suspect that this is an artifact of the SEER-Medicare data's reliance upon county-level income data rather than individual income data.
Our study highlights important disparities in hospice utilization among patients with MG. We found differences by race, sex, age, level of education, and rural versus urban residence. We also describe important predictors of a suboptimal short stay in hospice (≤3 days or ≤7 days), including younger age, male sex, and rural place of residence. We hope our findings will motivate additional research investigating ways to enhance EOL care for patients with MG. A better understanding of the barriers to earlier and more widespread hospice utilization for MG patients will facilitate the development of tailored interventions aimed at improving EOL care for this population with unique EOL care needs. 
